Medicine and HealthCell Discovery
Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
H. Ma, Y. Guo, et al.
Discover how researchers, including Hang Ma and Yingying Guo, have developed a groundbreaking monoclonal antibody, 2G1, that effectively neutralizes all current SARS-CoV-2 variants of concern. With high affinity and remarkable therapeutic efficacy, 2G1 showcases its potential to combat evolving threats in the pandemic landscape.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens
M. C. Miranda, E. Kepl, et al.
Medicine and Health
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
M. Dogan, L. Kozhaya, et al.
Medicine and Health
Human antibodies to SARS-CoV-2 with a recurring YYDRXG motif retain binding and neutralization to variants of concern including Omicron
H. Liu, C. I. Kaku, et al.
Medicine and Health
Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2
L. Wu, Q. Chen, et al.
